Clinical Trials Browser

Phase 1 × INDUSTRY × TAK-659 × Clear all

NCT02000934 2023-02-08

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Phase 1 Completed

LymphoidOther solid neoplasm

Advanced Solid Tumor and Lymphoma Malignancies

NCT02834247 2023-02-08

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase 1 Terminated

41 enrolled 24 charts

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT03238651 2023-02-08

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Phase 1 Terminated

17 enrolled 24 charts

Lymphoma, Lymphoma, Non-Hodgkin

NCT03338881 2023-02-08

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Phase 1 Withdrawn

Advanced Solid Neoplasms

NCT03357627 2023-02-08

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Phase 1 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03359733 2023-02-08

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Phase 1 Withdrawn

Lymphoma

NCT03772288 2023-02-08

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Phase 1 Withdrawn

Lymphoma, Non-Hodgkin